IL17A and psoriasis: We confirmed the therapeutic effect of XYJD on psoriasis, demonstrating its ability to significantly decrease the protein and mRNA expression levels of Th-17-related IL-23, IL-22, IL-17, and retinoid-related orphan nuclear receptor (ROR)-γt while balancing the Th17/Tregs in the peripheral blood of patients with psoriasis patients (Chen et al., 2020).